Avidicure
Develops AVC-Boosters to enhance NK cells, activate the immune system, and provide broad anti-tumor responses for cancer immunotherapy.
Employees
Enterprise value
$193—290m
Authorizing premium user...
Develops AVC-Boosters to enhance NK cells, activate the immune system, and provide broad anti-tumor responses for cancer immunotherapy.